# Blossom Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/blossom-biosciences

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Total disclosed funding: $72M
- Latest round: Series A (Jun 17, 2021)
- Investors on record: 2

## About

Based in Beijing, China and established in 2021, Bosheng Pharmaceutical is a medical company that focuses on drug development. The company was co-founded by Osprey Asset Management and Hansen Pharmaceutical Group. The company is committed to bringing potential breakthrough therapeutics to more patients in China, and Dr. Andrew Phillips, Managing Director of Fishhawk Capital Management and former CEO of C4 Therapeutics, Inc. is now acting CEO of the company. In June 2021, it closed a round of USD 72 million series A funding.

The company focuses on the development of therapeutic drugs and offers a full range of molecular and cell biology research methods, including mammalian cell culture, transfection, cell viability assays, IC50/EC50 studies, apoptosis, molecular cloning, WesternBlot and ELISA assays.

## Funding rounds

- Series A, Jun 17, 2021, $72M — Cormorant Asset Management, Hansoh Pharmaceutical

## Investors

- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Hansoh Pharmaceutical — Series A